Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06804057 · ClinicalTrials.gov registry record
CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry
A clinical trial of Systemic Lupus Erythematosus, sponsored by CorEvitas.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT06804057 is a study of Systemic Lupus Erythematosus that is actively recruiting participants, run by CorEvitas. The registered enrollment target is 1,000 participants, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06804057, a study of Systemic Lupus Erythematosus, is actively recruiting participants, sponsored by CorEvitas.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
Conditions Studied
Interventions
- OTHER Blood Collection
Study Locations (1)
Massachusetts
- CorEvitas - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-09-26 |
| Est. Completion | 2099-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06804057
The ClinicalTrials.gov registry entry for NCT06804057 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 370-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (170% higher). The listed sponsor is CorEvitas, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Blood Collection is the first listed.
NCT06804057 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06804057 about?
NCT06804057 is a clinical study titled "CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry". Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.
What is the current status of trial NCT06804057?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-09-26. Estimated completion is 2099-12-31.
What conditions does trial NCT06804057 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT06804057?
The interventions under investigation include: Blood Collection (OTHER).
Who is sponsoring clinical trial NCT06804057?
This trial is sponsored by CorEvitas, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06804057 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
RECRUITING · Phase 3
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
-
Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus
RECRUITING
-
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.